Literature DB >> 24607095

Product licences for alemtuzumab and multiple sclerosis.

Alasdair J Coles1, Alastair Compston2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24607095     DOI： 10.1016/S0140-6736(14)60440-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use.

Authors:  Eva Havrdova; Dana Horakova; Ivana Kovarova
Journal:  Ther Adv Neurol Disord       Date:  2015-01       Impact factor: 6.570

2.  Thyroid Storm in a Patient With Alemtuzumab-Induced Graves' Disease: A Case Report.

Authors:  Sara AlShehri; Sarah Alajmi; Aishah Ekhzaimy; Sadeem Aldawas; Maryam Alalwan
Journal:  Cureus       Date:  2022-04-28

Review 3.  Alemtuzumab for the treatment of multiple sclerosis.

Authors:  Mark D Willis; Neil P Robertson
Journal:  Ther Clin Risk Manag       Date:  2015-03-31       Impact factor: 2.423

Review 4.  The use of immune modulating drugs for the treatment of multiple sclerosis.

Authors:  Fahd A Al-Khamis
Journal:  Neurosciences (Riyadh)       Date:  2016-01       Impact factor: 0.735
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.